About Us
About Edge Our Culture Core Competence Reward and Qualification History
Products
Multi-Port Endoscopic Surgical Robotic System Single-Port Endoscopic Surgical Robotic System Natural Orifice Surgical Robotic System MIS Surgical Instruments
Empowerment Center
Collaboration Platform Patient Education Training Center
Contact Us
Contacts Feedback
EN
中文 En 繁体
About Us
Minimally invasive surgery innovative solution provider
Home
About Us
About Edge
About Edge Our Culture Core Competence Reward and Qualification History
About Edge
Shenzhen Edge Medical Co., Ltd. (Edge Medical) was founded by Dr. Wang Jianchen, who completed a joint PhD program at Massachusetts Institute of Technology, and Dr. Gao Yuanqian, who completed a joint PhD program at Harvard Medical School, on May 4, 2017. We are dedicated to the design, development and manufacturing of surgical robots, particularly surgical robots and instruments for minimally invasive surgery and providing innovative surgical solutions.
First company in China having completed the pivotal clinical trials of both multi-port and single-port endoscopic surgical robots

Extraordinary R&D Capabilities — Established a comprehensive proprietary intellectual property system with core technology modules in surgical robot. Over 500 patents grants and applications globally.


Support from leading investors worldwide  —  With RMB360 million registered capital, Edge Medical has successfully attracted investors with the deepest understanding of medical technology, including Boyu, Temasek, Sequoia, 3H Health, LYFE Capital, China State-Owned Enterprise Mixed Ownership Reform Fund and OrbiMed since established. Edge Medical was valued at over US$1.5 billion by the crossover round in December 2021.

Extraordinary R&D Capabilities  —  
As of January 3, 2023
No. 1
Edge®MP1000 is the first domestic endoscopic surgical robot to be applied in all departments of endoscopic surgeries
No. 1
China’s first company to complete key clinical trials of multi-port and single-port laparoscopic surgical robots
4
Four selected product pipelines with synergistic and complementary effect in technology, marketing and distribution
Our Culture
Mission
To advance surgical technology, empower surgeons and benefit patients
Vision
To equip every surgical room with surgical robot
Faith
To persistently pursuit of perfection in technologies to create the finest products
Core Competence
Our core team is comprised of scientists from the most prestigious domestic and international educational institutions including Massachusetts Institute of Technology, Harvard University, London Business School, and Peking University and experienced engineers from leading technology companies such as Siemens and Huawei. They specialize in a wide range of disciplines, including mechanical engineering, medicine, medical engineering, computer graphics, computer science, electronic engineering, hylology and artificial intelligence.
We established a comprehensive proprietary intellectual property system with core technologies in structural design, system control, motion planning and AI algorithms in 5 years.
＞
500
Over 500+ patents grants and applications globally
Reward and Qualification
2019
The company was rated as
the Top 50 of Technological and Innovative Enterprises in Guangdong-Hong Kong-Macau Greater Bay Area
2020
The company was rated as
the Top 50 of Biotechnology Enterprises in Guangdong-Hong Kong-Macau Greater Bay Area
2021
The company was rated as
the Top 100 of Fast-growing Enterprises in Shenzhen (ranked top 5)
2022
The company was rated as
Member of Shenzhen Robotics Association
2022
The company was rated as
Member of Shenzhen Medical Device Quality Promotion Association
2023
The company was rated as
Guangdong Surgical Robotics Engineering Research Center
Our History
To capitalize the vast market opportunities and address the unmet clinical needs in China, Edge Medical was dedicated to designing, developing, and manufacturing of surgical robots since its inception in 2017. we completed the design and major R&D of both Edge MP1000 and Edge SP1000 in only four years with both products being eligible for expedited review through the Green Path channel of the NMPA for innovative medical devices. In December 2022, we received the registration approval from the NMPA for MP1000.
2017~2019
2020~2021
2022~2023
2017~2019
Early stage of operation with the ambition to lead the transformation of the high-end medical devices market in China
2017
05
established in the PRC
2018
01
completed series Angel financing
2018
05
developed the prototype of SP1000 and completed the first animal testing, which was the first animal testing case performed using a single-port surgical robot in China;
2018
10
completed series A financing
2018
12
developed the prototype of MP1000 and completed the first animal testing
2019
10
developed the typeset products of both MP1000 and SP1000, and commenced pilot scale production
2020~2021
Strides in a competitive environment to lead the industry
2020
04
completed series A+ financing
2020
09
completed Pre-B financing
2022
12
completed type testing for both MP1000 and SP1000 with results strictly in conformity with relevant technical standards
2021
02
completed series B financing with over RMB 500 million
2021
04
SP1000 eligible for expedited review through the Green Path channel of the NMPA for innovative medical devices
2021
10
initiated the registrational clinical trial of SP1000 in gynecologic surgery (the first in China initiated pivotal clinical trial in gynecology for single-port endoscopic surgical robot)
2021
12
completed registrational clinical trial of MP1000 in urologic surgery
completed series crossover financing with over USD 200 million, post-money valuation is over USD 1.5 billion
partnership with Chinese Urological Association and Class III Grade A hospitals to build a national network of training centers
2022~2023
Continued pursuit of perfection and breakthrough to create the finest products
2022
01
developed the first generation prototype of Edge Bronchoscope Robot and completed the animal testing
2022
04
MP1000 eligible for expedited review through the Green Path channel of the NMPA for innovative medical devices
2022
06
completed patient enrollment for the registrational clinical trial of MP1000 in gynecologic surgery
2022
07
completed patient enrollment for the registrational clinical trial of SP1000 in gynecologic surgery
2022
10
received registration approval by Guangdong MPA for Edge® 3D Endoscope;
2022
11
patient enrollment for the registrational clinical trial of MP1000 in general and thoracic surgery completed;
2022
12
received registration approval by NMPA for MP1000